STAT Plus: Pharmalittle: NIH to test blood thinners against Covid-19; AbbVie employees feel pressured to return to work
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, not surprisingly, is quite modest. We plan to enjoy a library book, listen to new mixes of favorite old music, hang with a short person or two, and promenade with the official mascot. And what about you? This remains a fine time to enjoy the great outdoors. You could go online to ensure your mail-in ballot is on its way. Or you could reach out to someone feeling isolated these days. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …
U.S. researchers have begun two clinical trials examining the use of blood thinners to help Covid-19 patients avoid clotting that has led to strokes, heart attacks, and organ failure, Bloomberg News writes. In one study, the National Institutes of Health will look at the use of apixaban in people who have not been hospitalized. Apixaban is sold under the brand name Eliquis by Bristol Myer Squibb (BMY) and Pfizer (PFE), with the first generic versions approved last year. The other trial will study the use of heparin in patients who are hospitalized.
Continue to STAT Plus to read the full story…
